Healthcare Industry News: Medrad
News Release - July 23, 2007
MEDRAD(R) Announces New Head of Magnetic Resonance Business UnitWARRENDALE, Pa., July 23 (HSMN NewsFeed) -- Joseph Havrilla has been named senior vice president of Medrad, INC.'s Magnetic Resonance Strategic Business Unit, responsible for overseeing the development and marketing of Medrad's full line of MR-compatible accessories and patient care products. Havrilla will also continue in his role as senior vice president of Corporate Innovation, a position he has held since 2003. "We owe much of Medrad's worldwide reputation for innovation to the efforts of Joe and his team," says Medrad President and CEO John P. Friel. "He brings the historical perspective to his new role, coupled with the depth of experience to enable us to meet our aggressive product development goals."
Havrilla joined Medrad in 1983 as a research engineer, and has been a consistent contributor to Medrad's technical excellence for 24 years. Promoted through Medrad's new product development organization, his team brought some of Medrad's most innovative products to market, including MCT/MCT+, the Front Load Syringe, Mark V, Envision®, Stellant®, prefilled cartridges, Spectris® and Spectris Solaris®, ProVis® and the 9500 monitor line. He also personally holds over two dozen patents.
Medrad has delivered advanced technology to the MR suite for over a decade, and its MR revenues have experienced double-digit growth in recent years. Leading Medrad MR products include the Spectris Solaris® EP Injection System, Continuum MR Infusion System, Leading Image(TM) Coils and the Veris MR Patient Monitor, winner of the Frost & Sullivan Customer Value Enhancement Award in 2005.
The role of senior vice president of the MR SBU was formerly held by Gary Bucciarelli, who has been named Medrad's chief administration officer.
Medrad, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, Medrad's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were $478 million. Medrad is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. Medrad is an affiliate of Bayer AG. More company information is available at http://www.Medrad.com.
Bayer AG is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. The company's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Medrad's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Medrad, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.